Restricted accessResearch articleFirst published online 2021-03
Assessment of the Effects of Altered Amyloid-Beta Clearance on Behavior following Repeat Closed-Head Brain Injury in Amyloid-Beta Precursor Protein Humanized Mice
Traumatic brain injury (TBI) increases the risk for dementias including Alzheimer's disease (AD) and chronic traumatic encephalopathy. Further, both human and animal model data indicate that amyloid-beta (Aβ) peptide accumulation and its production machinery are upregulated by TBI. Considering the clear link between chronic Aβ elevation and AD as well as tau pathology, the role(s) of Aβ in TBI is of high importance. Endopeptidases, including the neprilysin (NEP)-like enzymes, are key mediators of Aβ clearance and may affect susceptibility to pathology post-TBI. Here, we use a “humanized” mouse model of Aβ production, which expresses normal human amyloid-beta precursor protein (APP) under its natural transcriptional regulation and exposed them to a more clinically relevant repeated closed-head TBI paradigm. These transgenic mice also were crossed with mice deficient for the Aβ degrading enzymes NEP or NEP2 to assess models of reduced cerebral Aβ clearance in our TBI model. Our results show that the presence of the human form of Aβ did not exacerbate motor (Rotarod) and spatial learning/memory deficits (Morris water maze) post-injuries, while potentially reduced anxiety (Open Field) was observed. NEP and NEP2 deficiency also did not exacerbate these deficits post-injuries and was associated with protection from motor (NEP and NEP2) and spatial learning/memory deficits (NEP only). These data suggest that normally regulated expression of wild-type human APP/Aβ does not contribute to deficits acutely after TBI and may be protective at this stage of injury.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention. (2014). Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths—United States. www.cdc.gov/traumaticbraininjury/pdf/TBI-Surveillance-Report-FINAL_508.pdf (Last accessed November23, 2020).
2.
BailesJ.E., PetragliaA.L., OmaluB.I., NaumanE., and TalavageT. (2013). Role of subconcussion in repetitive mild traumatic brain injury. J. Neurosurg. 119, 1235–1245.
3.
DashnawM.L., PetragliaA.L., and BailesJ.E. (2012). An overview of the basic science of concussion and subconcussion: where we are and where we are going. Neurosurg. Focus, 33, 1–9.
4.
TurnerR.C., Lucke-WoldB.P., RobsonM.J., OmaluB.I., PetragliaA.L., and BailesJ.E. (2012). Repetitive traumatic brain injury and development of chronic traumatic encephalopathy: a potential role for biomarkers in diagnosis, prognosis, and treatment?. Front. Neurol. 3, 186.
5.
Al-DahhakR., KhouryR., QaziE., and GrossbergG.T. (2018). Traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer disease. Clinics in geriatric medicine, 34, 617–635.
6.
LoBueC., MunroC., SchaffertJ., DidehbaniN., HartJ., BatjerH., and CullumC.M. (2019). Traumatic brain injury and risk of long-term brain changes, accumulation of pathological markers, and developing dementia: a review. J. Alzheimers Dis. 70, 629–654.
7.
PerryD.C., SturmV.E., PetersonM.J., PieperC.F., BullockT., BoeveB.F., MillerB.L., GuskiewiczK.M., BergerM.S., KramerJ.H., and Welsh-BohmerK.A. (2016). Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis. J. Neurosurg. 124, 511–526.
8.
BlennowK., HardyJ., and ZetterbergH. (2012). The neuropathology and neurobiology of traumatic brain injury. Neuron, 76, 886–899.
9.
JohnsonV.E., StewartW., and SmithD.H. (2012). Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 22, 142–149.
10.
ChenX.H., JohnsonV.E., UryuK., TrojanowskiJ.Q., and SmithD.H. (2009). A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol. 19, 214–223.
11.
GatsonJ.W., WarrenV., AbdelfattahK., WolfS., HynanL.S., MooreC., Diaz-ArrastiaR., MineiJ.P., MaddenC., and WiggintonJ.G. (2013). Detection of beta-amyloid oligomers as a predictor of neurological outcome after brain injury. J. Neurosurg. 118, 1336–1342.
12.
MarklundN., FarrokhniaN., HanellA., VanmechelenE., EnbladP., ZetterbergH., BlennowK., and HilleredL. (2014). Monitoring of beta-amyloid dynamics after human traumatic brain injury. J. Neurotrauma, 31, 42–55.
13.
HongY.T., VeenithT., DewarD., OuttrimJ.G., ManiV., WilliamsC., PimlottS., HutchinsonP.J., TavaresA., CanalesR., MathisC.A., KlunkW.E., AigbirhioF.I., ColesJ.P., BaronJ.C., PickardJ.D., FryerT.D., StewartW., and MenonD.K. (2014). Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol. 71, 23–31.
14.
ScottG., RamlackhansinghA.F., EdisonP., HellyerP., ColeJ., VeroneseM., LeechR., GreenwoodR.J., TurkheimerF.E., GentlemanS.M., HeckemannR.A., MatthewsP.M., BrooksD.J., and SharpD.J. (2016). Amyloid pathology and axonal injury after brain trauma. Neurology, 86, 821–828.
15.
YangS.T., HsiaoI.T., HsiehC.J., ChiangY.H., YenT.C., ChiuW.T., LinK.J., and HuC.J. (2015). Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. J. Neurol. Sci. 349, 99–104.
16.
MohamedA.Z., CummingP., SrourH., GunasenaT., UchidaA., HallerC.N., NasrallahF. and Department of Defense Alzheimer's Disease NeuroimagingI. (2018). Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury. NeuroImage. Clin. 19, 716–726.
17.
ChoiS.H., KimY.H., HebischM., SliwinskiC., LeeS., D'AvanzoC., ChenH., HooliB., AsselinC., MuffatJ., KleeJ.B., ZhangC., WaingerB.J., PeitzM., KovacsD.M., WoolfC.J., WagnerS.L., TanziR.E., and KimD.Y. (2014). A three-dimensional human neural cell culture model of Alzheimer's disease. Nature, 515, 274–278.
18.
GotzJ., ChenF., van DorpeJ., and NitschR.M. (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science, 293, 1491–1495.
19.
LewisJ., DicksonD.W., LinW.L., ChisholmL., CorralA., JonesG., YenS.H., SaharaN., SkipperL., YagerD., EckmanC., HardyJ., HuttonM., and McGowanE. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 293, 1487–1491.
20.
OddoS., CaccamoA., ShepherdJ.D., MurphyM.P., GoldeT.E., KayedR., MetherateR., MattsonM.P., AkbariY., and LaFerlaF.M. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 39, 409–421.
21.
BennettD.A., SchneiderJ.A., WilsonR.S., BieniasJ.L., Berry-KravisE., and ArnoldS.E. (2005). Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J. Neurol. Neurosurg. Psychiatry, 76, 1194–1199.
22.
BennettD.A., SchneiderJ.A., WilsonR.S., BieniasJ.L., and ArnoldS.E. (2004). Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 61, 378–384.
23.
BennettD.A., WilsonR.S., SchneiderJ.A., EvansD.A., AggarwalN.T., ArnoldS.E., CochranE.J., Berry-KravisE., and BieniasJ.L. (2003). Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology, 60, 246–252.
24.
BocheD., DonaldJ., LoveS., HarrisS., NealJ.W., HolmesC., and NicollJ.A. (2010). Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol. 120, 13–20.
25.
ChabrierM.A., Blurton-JonesM., AgazaryanA.A., NerhusJ.L., Martinez-CoriaH., and LaFerlaF.M. (2012). Soluble abeta promotes wild-type tau pathology in vivo. J. Neurosci. 32, 17345–17350.
EdwardsG., 3rdMoreno-Gonzalez, I., and SotoC. (2017). Amyloid-beta and tau pathology following repetitive mild traumatic brain injury. Biochem. Biophys. Res. Commun. 483, 1137–1142.
28.
LoaneD.J., PocivavsekA., MoussaC.E., ThompsonR., MatsuokaY., FadenA.I., RebeckG.W., and BurnsM.P. (2009). Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nat. Med. 15, 377–379.
29.
ChenX.H., SimanR., IwataA., MeaneyD.F., TrojanowskiJ.Q., and SmithD.H. (2004). Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am. J. Pathol. 165, 357–371.
30.
MannixR.C., ZhangJ., ParkJ., LeeC., and WhalenM.J. (2011). Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice. J. Neurotrauma, 28, 1855–1861.
31.
SmithD.H., NakamuraM., McIntoshT.K., WangJ., RodriguezA., ChenX.H., RaghupathiR., SaatmanK.E., ClemensJ., SchmidtM.L., LeeV.M., and TrojanowskiJ.Q. (1998). Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am. J. Pathol. 153, 1005–1010.
32.
TajiriN., KelloggS.L., ShimizuT., ArendashG.W., and BorlonganC.V. (2013). Traumatic brain injury precipitates cognitive impairment and extracellular Abeta aggregation in Alzheimer's disease transgenic mice. PloS One, 8, e78851.
33.
TranH.T., LaFerlaF.M., HoltzmanD.M., and BrodyD.L. (2011). Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-beta accumulation and independently accelerates the development of tau abnormalities. J. Neurosci. 31, 9513–9525.
34.
TranH.T., SanchezL., EsparzaT.J., and BrodyD.L. (2011). Distinct temporal and anatomical distributions of amyloid-beta and tau abnormalities following controlled cortical impact in transgenic mice. PloS One, 6, e25475.
35.
UryuK., LaurerH., McIntoshT., PraticoD., MartinezD., LeightS., LeeV.M., and TrojanowskiJ.Q. (2002). Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22, 446–454.
36.
WashingtonP.M., MorffyN., ParsadanianM., ZappleD.N., and BurnsM.P. (2014). Experimental traumatic brain injury induces rapid aggregation and oligomerization of amyloid-beta in an Alzheimer's disease mouse model. J. Neurotrauma, 31, 125–134.
37.
WebsterS.J., Van EldikL.J., WattersonD.M., and BachstetterA.D. (2015). Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment. J Neurosci, 35, 6554–6569.
38.
Levy NogueiraM., HamrazM., AbolhassaniM., BiganE., LafitteO., SteyaertJ.M., DuboisB., and SchwartzL. (2018). Mechanical stress increases brain amyloid beta, tau, and alpha-synuclein concentrations in wild-type mice. Alzheimers Dement. 14, 444–453.
39.
ShishidoH., UenoM., SatoK., MatsumuraM., ToyotaY., KirinoY., TamiyaT., KawaiN., and KishimotoY. (2019). Traumatic brain injury by weight-drop method causes transient amyloid-beta deposition and acute cognitive deficits in mice. Behav. Neurol. 2019, 3248519.
40.
IwataN., TsubukiS., TakakiY., ShirotaniK., LuB., GerardN.P., GerardC., HamaE., LeeH.J., and SaidoT.C. (2001). Metabolic regulation of brain Abeta by neprilysin. Science, 292, 1550–1552.
41.
IwataN., TsubukiS., TakakiY., WatanabeK., SekiguchiM., HosokiE., Kawashima-MorishimaM., LeeH.J., HamaE., Sekine-AizawaY., and SaidoT.C. (2000). Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143–150.
42.
MarrR.A. and SpencerB.J. (2010). NEP-like Endopeptidases and Alzheimer's Disease. Current Alzheimer research, 7, 223–229.
43.
EckmanE.A., AdamsS.K., TroendleF.J., StodolaB.A., KahnM.A., FauqA.H., XiaoH.D., BernsteinK.E., and EckmanC.B. (2006). Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J. Biol. Chem. 281, 30471–30478.
44.
MadaniR., PoirierR., WolferD.P., WelzlH., GroscurthP., LippH.P., LuB., El MoueddenM., MerckenM., NitschR.M., and MohajeriM.H. (2006). Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J. Neurosci. Res. 84, 1871–1878.
JohnsonV.E., StewartW., GrahamD.I., StewartJ.E., PraestgaardA.H., and SmithD.H. (2009). A neprilysin polymorphism and amyloid-beta plaques after traumatic brain injury. J. Neurotrauma, 26, 1197–1202.
47.
MarrR.A. and HafezD.M. (2014). Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance. Front. Aging Neurosci. 6, 187.
48.
HafezD., HuangJ.Y., HuynhA.M., ValtierraS., RockensteinE., BrunoA.M., LuB., DesGroseillersL., MasliahE., and MarrR.A. (2011). Neprilysin-2 is an important beta-amyloid degrading enzyme. Am. J. Pathol. 178, 306–312.
49.
HuangJ.Y., BrunoA.M., PatelC.A., HuynhA.M., PhilibertK.D., GlucksmanM.J., and MarrR.A. (2008). Human membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40. Neuroscience, 155, 258–262.
50.
HansonL.R., HafezD., SvitakA.L., BurnsR.B., LiX., FreyW.H. 2nd, and MarrR.A. (2010). Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice. J. Mol. Neurosci. 43, 424–427.
51.
HuangJ.Y., HafezD.M., JamesB.D., BennettD.A., and MarrR.A. (2012). Altered NEP2 Expression and Activity in Mild Cognitive Impairment and Alzheimer's Disease. J. Alzheimers Dis. 28, 433–441.
52.
LambB.T., SisodiaS.S., LawlerA.M., SluntH.H., KittC.A., KearnsW.G., PearsonP.L., PriceD.L., and GearhartJ.D. (1993). Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. Nat. Genet. 5, 22–30.
53.
CarpentierM., GuillemetteC., BaileyJ.L., BoileauG., JeannotteL., DesGroseillersL., and CharronJ. (2004). Reduced fertility in male mice deficient in the zinc metallopeptidase NL1. Molec. Cell. Biol. 24, 4428–4437.
54.
MouzonB., ChaytowH., CrynenG., BachmeierC., StewartJ., MullanM., StewartW., and CrawfordF. (2012). Repetitive mild traumatic brain injury in a mouse model produces learning and memory deficits accompanied by histological changes. J. Neurotrauma, 29, 2761–2773.
55.
HsiaoK.K., BorcheltD.R., OlsonK., JohannsdottirR., KittC., YunisW., XuS., EckmanC., YounkinS., PriceD., ladecolaC., ClarkH.B., and CarlsonG. (1995). Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron, 15, 1203–1218.
56.
FarrisW., SchutzS.G., CirritoJ.R., ShankarG.M., SunX., GeorgeA., LeissringM.A., WalshD.M., QiuW.Q., HoltzmanD.M., and SelkoeD.J. (2007). Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 171, 241–251.
57.
KokuboH., KayedR., GlabeC.G., StaufenbielM., SaidoT.C., IwataN., and YamaguchiH. (2009). Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int. J. Alzheimers Dis. 2009, 689285.
58.
HafezD.M., HuangJ.Y., RichardsonJ.C., MasliahE., PetersonD.A., and MarrR.A. (2012). F-spondin gene transfer improves memory performance and reduces amyloid-beta levels in mice. Neuroscience, 223, 465–472.
59.
PetragliaA.L., PlogB.A., DayawansaS., ChenM., DashnawM.L., CzernieckaK., WalkerC.T., ViteriseT., HyrienO., IliffJ.J., DeaneR., NedergaardM., and HuangJ.H. (2014). The spectrum of neurobehavioral sequelae after repetitive mild traumatic brain injury: a novel mouse model of chronic traumatic encephalopathy. J. Neurotrauma, 31, 1211–1224.
60.
WebsterS.J., BachstetterA.D., NelsonP.T., SchmittF.A., and Van EldikL.J. (2014). Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front. Genet. 5, 88.
61.
MarrR. (2016). The amyloid β precursor protein and cognitive function in Alzheimer's disease, in: Genes Environment and Alzheimer's Disease. LazarovO. and TescoG. (eds). Elsevier: Amsterdam, the Netherlands, pps. 97–113.
62.
MannixR.C., ZhangJ., BerglassJ., QuiJ., and WhalenM.J. (2013). Beneficial effect of amyloid beta after controlled cortical impact. Brain Inj. 27, 743–748.
63.
CorriganF., VinkR., BlumbergsP.C., MastersC.L., CappaiR., and van den HeuvelC. (2012). Characterisation of the effect of knockout of the amyloid precursor protein on outcome following mild traumatic brain injury. Brain Res. 1451, 87–99.
64.
CorriganF., VinkR., BlumbergsP.C., MastersC.L., CappaiR., and van den HeuvelC. (2012). sAPPalpha rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. J. Neurochem. 122, 208–220.
65.
Pajoohesh-GanjiA., BurnsM.P., Pal-GhoshS., TadvalkarG., HokenburyN.G., SteppM.A., and FadenA.I. (2014). Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury. Brain Res. 1560, 73–82.
66.
BrodyD.L., MagnoniS., SchwetyeK.E., SpinnerM.L., EsparzaT.J., StocchettiN., ZipfelG.J., and HoltzmanD.M. (2008). Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science, 321, 1221–1224.
67.
TurnerA.J., IsaacR.E., and CoatesD. (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays, 23, 261–269.
68.
MarrR. (2013). Neprilysin-2, in: Handbook of Proteolytic Enzymes. N.D. Rawlings and G. Salvesen (eds). Academic Press:, Oxford, U.K.
69.
RoseC., VoisinS., GrosC., SchwartzJ.C., and OuimetT. (2002). Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem. J. 363, 697–705.
70.
LuB., GerardN.P., KolakowskiL.F.Jr., BozzaM., ZurakowskiD., FincoO., CarrollM.C., and GerardC. (1995). Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181, 2271–2275.
71.
SturialeS., BarbaraG., QiuB., FiginiM., GeppettiP., GerardN., GerardC., GradyE.F., BunnettN.W., and CollinsS.M. (1999). Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc. Natl. Acad. Sci. U. S. A. 96, 11653–11658.
72.
TrivediA., Noble-HaeussleinL.J., LevineJ.M., SantucciA.D., ReevesT.M., and PhillipsL.L. (2019). Matrix metalloproteinase signals following neurotrauma are right on cue. Cell. Molec. Life Sci. 76, 3141–3156.
73.
ShenR., SumitomoM., DaiJ., HardyD.O., NavarroD., UsmaniB., PapandreouC.N., HershL.B., ShippM.A., FreedmanL.P., and NanusD.M. (2000). Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Molec. Cell. Endocrinol. 170, 131–142.
74.
ZhengR., ShenR., GoodmanO.B.Jr., and NanusD.M. (2006). Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter. Molec. Cell. Endocrinol. 259, 10–21.
75.
RoseJ.B., CrewsL., RockensteinE., AdameA., ManteM., HershL.B., GageF.H., SpencerB., PotkarR., MarrR.A., and MasliahE. (2009). Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J. Neurosci. 29, 1115–1125.
76.
JamniaN., UrbanJ.H., StutzmannG.E., ChirenS.G., ReisenbiglerE., MarrR., PetersonD.A., and KozlowskiD.A. (2017). A clinically relevant closed-head model of single and repeat concussive injury in the adult rat using a controlled cortical impact device. J. Neurotrauma, 34, 1351–1363.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
